Developer of new generation drugs designed to improve the current treatment strategies for a variety of diseases. The company's drugs act within a targeted diseased tissue and modify therapeutic proteins to achieve substantial control over pharmacokinetics, enabling physicians to treat their patients in an enhanced way.
Pre-Clinical Trials
Privately Held (backing)
Venture Capital-Backed
The company raised $1.72 million of Series A venture funding from ShangPharma Innovation and other undisclosed investors on September 21, 2018, putting the company's pre-money valuation at $5 million. Earlier, the company joined The House Fund on February 1, 2018 and received $20,000 in funding.
Add a review